Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Iparomlimab and Tuvonralimab Combined With Paclitaxel and Bevacizumab for the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Failed First-Line Treatment With PD-(L)1 Inhibitor Combined With Chemotherapy

NCT07045805 is registered in ClinicalTrials.gov with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor.

NCT NCT07045805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07045805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Iparomlimab and Tuvonralimab Combined With Paclitaxel and Bevacizumab for the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Failed First-Line Treatment With PD-(L)1 Inhibitor Combined With Chemotherapy
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 25, 2025
Completion date
March 31, 2028
Enrollment
66 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer (gc)